Abstract
Mephedrone (4-methylmethcathinone, MMC) and 3,4-methylenedioxymethamphetamine (MDMA) are constituents of popular party drugs with psychoactive effects. Structurally they are amphetamine-like substances with monoamine neurotransmitter enhancing actions. We therefore compared their effects on the human monoamine transporters using human cell lines stably expressing the human noradrenaline, dopamine and serotonin transporter (NET, DAT and SERT); preparations of synaptic vesicles from human striatum in uptake experiments; and a superfusion system where releasing effects can be reliably measured. MMC and MDMA were equally potent in inhibiting noradrenaline uptake at NET, with IC50 values of 1.9 and 2.1 µM, respectively. Compared to their NET inhibition potency, both drugs were weaker uptake inhibitors at DAT and SERT, with MMC being more potent than MDMA at DAT (IC50: 5.9 vs 12.6 µM) and less potent than MDMA at SERT (IC50: 19.3 vs 7.6 µM). MMC and MDMA both induced concentration-dependently [(3)H]1-methyl-4-phenylpyridinium-release from NET-, DAT or SERT-expressing cells which was clearly transporter-mediated release as demonstrated by the selective inhibitory effects of nmolar to low µmolar concentrations of desipramine, GBR 12909...Continue Reading
References
Aug 1, 1995·Molecular Neurobiology·D B Miller, J P O'Callaghan
Nov 9, 2000·Synapse·R B RothmanJ S Partilla
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·J Paul HansenAnnette E Fleckenstein
Aug 16, 2002·The Journal of Physiology·Doris KristufekSigismund Huck
May 14, 2003·Neurochemistry International·Inger Lise BogenFrode Fonnum
Jul 19, 2003·Pharmacological Reviews·A Richard GreenM Isabel Colado
Nov 25, 2005·Journal of Pharmaceutical Sciences·Tomoe FujitaKathleen M Giacomini
Jul 5, 2008·Molecular Pharmacology·Masahiko Watabe, Toshio Nakaki
Mar 28, 2009·Nuclear Medicine and Biology·Melanie BayerGernot Bruchelt
Jul 29, 2011·Drug and Alcohol Dependence·Russell C CallaghanStephen J Kish
Aug 4, 2011·The Journal of Pharmacology and Experimental Therapeutics·Gregory C HadlockAnnette E Fleckenstein
Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael H BaumannNicholas V Cozzi
Apr 19, 2012·British Journal of Pharmacology·Raul López-ArnauJorge Camarasa
Aug 18, 2012·British Journal of Pharmacology·L D SimmlerM E Liechti
Oct 27, 2012·Pharmacology, Biochemistry, and Behavior·Bjørnar den HollanderEsa R Korpi
Nov 28, 2012·European Journal of Pharmacology·Michael H BaumannKurt R Lehner
Dec 25, 2012·European Journal of Pharmacology·Les IversenBryan L Roth
Jan 11, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·D P DaberkowM F Roitman
Apr 16, 2013·Biochemical Pharmacology·Amy J EshlemanAaron Janowsky
Feb 7, 2014·Molecular Pharmacology·Karl T Schmidt, David Weinshenker
Mar 25, 2014·British Journal of Pharmacology·A R GreenK C F Fone
Citations
Oct 27, 2015·Neurotoxicity Research·Krystyna GołembiowskaAnna Górska
Jul 9, 2016·British Journal of Pharmacology·F P MayerH H Sitte
Jan 30, 2018·Frontiers in Psychiatry·Klára ŠíchováTomáš Páleníček
Aug 4, 2018·Psychopharmacology·John H AnnekenDonald M Kuhn
Dec 6, 2018·Current Computer-aided Drug Design·Kobra ForoughiAsghar Shayannia
Jun 9, 2020·Frontiers in Pharmacology·Marija IlicDino Luethi
Feb 23, 2020·Brain Research·Jessica Mead, Andrew Parrott
Apr 1, 2021·British Journal of Pharmacology·James R Docherty, Hadeel A Alsufyani
Nov 4, 2017·Pharmacology & Therapeutics·Laura HondebrinkRemco H S Westerink
Jun 9, 2021·Archives of Toxicology·Jorge SoaresJoão Paulo Capela
Jul 17, 2021·Psychopharmacology·Olga WronikowskaBarbara Budzyńska
Jul 11, 2021·Molecular Psychiatry·Jana LubecGert Lubec
Aug 17, 2021·Journal of Clinical Pharmacology·James R Docherty, Hadeel A Alsufyani
Oct 3, 2018·ACS Chemical Neuroscience·Julian MaierHarald H Sitte
Dec 17, 2019·Journal of Medicinal Chemistry·Predrag KalabaGert Lubec